SCHEMBL5136565

SCHEMBL5136565

CCCCn1c(-c2ccccc2OC)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccc(O)cc1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L2 Q92843 1/20 0.36
HTR1A P08908 3/20 0.36
HTR2B P41595 3/20 0.36
HTR2C P28335 2/20 0.36
C5AR1 P21730 1/20 0.35
HTR7 P34969 2/20 0.35
HTR5A P47898 2/20 0.35
HTR6 P50406 1/20 0.35
PDK1 Q15118 2/20 0.35
BCHE P06276 3/20 0.34
KMT2A Q03164 3/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 2/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 2/20 0.33
TSHR P16473 2/20 0.33
GFER P55789 1/20 0.33
TAAR1 Q96RJ0 1/20 0.32
HPGD P15428 1/20 0.32
HTR1D P28221 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136452 0.93 HDAC1 (0.36) BCL2L2HTR1AHTR2BHTR2CC5AR1
SCHEMBL4764487 0.89 C5AR1 (0.43) C5AR1PDK1KMT2AKDM4EMEN1
SCHEMBL5136841 0.88 C5AR1 (0.39) C5AR1PDK1BCHEKMT2AKDM4E
SCHEMBL4766462 0.88 TLR7 (0.41) C5AR1PDK1KMT2AMEN1
SCHEMBL5135930 0.87 C5AR1 (0.36) BCL2L2HTR1AHTR2BHTR2CC5AR1
SCHEMBL5136126 0.86 C5AR1 (0.40) C5AR1PDK1TSHR
SCHEMBL5138072 0.85 C5AR1 (0.43) C5AR1KMT2AKDM4EMEN1ALDH1A1
SCHEMBL5135487 0.84 BCHE (0.38) BCL2L2HTR1AHTR2BHTR2CC5AR1
SCHEMBL14099515 0.83 BCL2L2 (0.39) BCL2L2HTR1AHTR2BHTR2CC5AR1
SCHEMBL5136216 0.83 C5AR1 (0.41) C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed